US8748435, 39

ID: ALA3639746

PubChem CID: 86766090

Max Phase: Preclinical

Molecular Formula: C27H39N5

Molecular Weight: 433.64

Molecule Type: Small molecule

Names and Identifiers

Canonical SMILES:  CCc1nn2c(C)cc(C)nc2c1Cc1ccc(CCCN2CCN(C(C)C)CC2)cc1

Standard InChI:  InChI=1S/C27H39N5/c1-6-26-25(27-28-21(4)18-22(5)32(27)29-26)19-24-11-9-23(10-12-24)8-7-13-30-14-16-31(17-15-30)20(2)3/h9-12,18,20H,6-8,13-17,19H2,1-5H3

Standard InChI Key:  DFFKMCAWTADECS-UHFFFAOYSA-N

Molfile:  

     RDKit          2D

 32 35  0  0  0  0  0  0  0  0999 V2000
    3.7551   -4.4175    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.5551   -4.4192    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.8032   -3.1233    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4133   -1.7530    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.2990   -0.7500    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.2990    0.7500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.3383    1.3500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000    1.5000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2990    0.7500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3383    1.3500    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2990   -0.7500    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.0000   -1.5000    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3114   -2.9665    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6890   -4.0818    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.2234   -5.5086    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.2234   -6.6267    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.7552   -8.0517    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7130   -8.3588    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.1844   -9.7837    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.6539  -10.0888    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.1253  -11.5137    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5948  -11.8188    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.0680  -13.2422    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.5373  -13.5442    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.5334  -12.4227    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    7.0603  -10.9993    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.5910  -10.6973    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.0042  -12.7219    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.7998  -11.8236    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.3847  -13.8599    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7131   -7.2408    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.2449   -5.8157    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  1  0
  2  3  1  0
  3  4  2  0
  4  5  1  0
  5  6  1  0
  6  7  1  0
  6  8  2  0
  8  9  1  0
  9 10  1  0
  9 11  2  0
 11 12  1  0
 12  5  1  0
 12 13  2  0
 13  3  1  0
 13 14  1  0
 14 15  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  1  0
 20 21  1  0
 21 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  1  0
 25 26  1  0
 26 27  1  0
 27 22  1  0
 25 28  1  0
 28 29  1  0
 28 30  1  0
 18 31  1  0
 31 32  2  0
 32 15  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA3639746

   2-Ethyl-5,7-dimethyl-3-[[4-[3-(4-propan-2-ylpiperazin-1-yl)propyl]phenyl]methyl]pyrazolo[1,5-a]pyrimidine

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 433.64

Molecular Weight (Monoisotopic): 433.3205

AlogP: 4.46

#Rotatable Bonds: 8

Polar Surface Area: 36.67

Molecular Species: BASE

HBA: 5

HBD: ┄

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): ┄

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 8.66

CX LogP: 5.20

CX LogD: 3.92

Aromatic Rings: 3

Heavy Atoms: 32

QED Weighted: 0.53

Np Likeness Score: -1.46

References

1.  (2014)  Pyrazolo pyrimidine derivatives, 

2. Velcicky J, Miltz W, Oberhauser B, Orain D, Vaupel A, Weigand K, Dawson King J, Littlewood-Evans A, Nash M, Feifel R, Loetscher P..  (2017)  Development of Selective, Orally Active GPR4 Antagonists with Modulatory Effects on Nociception, Inflammation, and Angiogenesis.,  60  (9): [PMID:28445047] [10.1021/acs.jmedchem.6b01703]

Source

Source(2):

• Scientific Literature
• BindingDB Database